Novo Nordisk A S annual cash and equivalents
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Cash & Equivalents Growth & History (NVO)
Novo Nordisk A S's cash and equivalents was kr26.46B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr26.46B | kr10.81B | +69.05% |
| 2024 | 2024-12-31 | kr15.65B | kr1.26B | +8.78% |
| 2023 | 2023-12-31 | kr14.39B | kr1.74B | +13.74% |
| 2022 | 2022-12-31 | kr12.65B | kr1.93B | +18.04% |
| 2021 | 2021-12-31 | kr10.72B | −kr1.51B | −12.33% |
| 2020 | 2020-12-31 | kr12.23B | −kr3.19B | −20.67% |
| 2019 | 2019-12-31 | kr15.41B | — | — |
Novo Nordisk A S quarterly cash and equivalents
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr44.48B | kr26.05B | +141.29% |
| Q1 2026 | 2026-03-31 | kr21.13B | — | — |
| Q4 2025 | 2025-12-31 | kr26.46B | kr10.81B | +69.05% |
| Q3 2025 | 2025-09-30 | kr32.08B | — | — |
| Q2 2025 | 2025-06-30 | kr18.43B | — | — |
| Q4 2024 | 2024-12-31 | kr15.65B | kr1.26B | +8.78% |
| Q4 2023 | 2023-12-31 | kr14.39B | kr1.74B | +13.74% |
| Q4 2022 | 2022-12-31 | kr12.65B | kr1.93B | +18.04% |
| Q4 2021 | 2021-12-31 | kr10.72B | — | — |
Novo Nordisk A S cash and equivalents trends
Over the last five fiscal years, Novo Nordisk A S's cash and equivalents increased from kr12.23B to kr26.46B, a change of kr14.24B. The latest reported quarter, Q2 2026, shows kr44.48B.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...